Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Direct Blood Volume Measurement in the Treatment of Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>21 years~* Discharge from hospital or emergency department observation unit with a primary diagnosis of acute decompensated heart failure~* Planned discharge home~* Able and willing to provide informed consent~Exclusion Criteria:~* Significant co-morbidity during heart failure hospitalization (treated pneumonia, sepsis, respiratory failure, oliguric renal failure, major bleeding requiring transfusion, stroke)~* Heart failure primarily due to significant valvular disease, sub-aortic outflow obstruction, active myocardial ischemia, apical ballooning syndrome, active arrhythmias, active myocarditis, primary restrictive cardiomyopathy, pericardial disease, or congenital heart disease~* Other major co-morbidities that increase mortality risk (stroke with hemiplegia, diabetes with end-organ damage other than heart disease, history of cancer in last 2 years, moderate to severe liver disease, HIV infection with AIDS)~* Hospitalization length of stay \>10 days~* Evidence of acute coronary syndrome during qualifying heart failure hospitalization~* Planned revascularization procedure within 6 months~* Planned implantation of ICD or pacemaker within 6 months~* Planned placement on cardiac transplantation list within 6 months~* Planned other major cardiac surgery or other surgery within 6 months~* Planned intermittent or continuous intravenous positive inotropic therapy~* Planned intermittent or continuous intravenous vasodilator therapy~* Severe obesity (BMI ≥ 40 kg/m2) or cachexia (BMI ≤18 kg/m2)~* Severe chronic kidney disease (estimated GFR\<30 ml/min (Modification of Diet in Renal Disease formula20))~* Hemoglobin \< 10 gm/dl~* Non-cardiac primary limitation to exercise (rheumatological, orthopedic, pulmonary, neurological or peripheral vascular disease)~* Known history of non-adherence with medications~* Psycho-social factors that interfere with ability to adhere to study procedures (dementia, active substance abuse, poorly controlled psychiatric illnesses, inability to travel frequently to the study center)~* Pregnant women or nursing mothers~* Women of childbearing potential not using adequate birth control methods~* Known hypersensitivity to iodine, eggs, or any other component of the Volumex injection kit~* History of anaphylaxis~* Participation in another heart failure investigational treatment protocol currently or \<30 days

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daxor Blood Volume Analysis (Type: EXPERIMENTAL): Subjects in this treatment arm will receive guideline recommended treatment based on direct blood volume measurement for assessment of volume status.
- Clinical volume status assessment (Type: ACTIVE_COMPARATOR): Subjects in this treatment arm will receive guideline recommended treatment based on clinical assessment of volume status.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues